SCHEMBL3016703

SCHEMBL3016703

COc1ccc(Br)cc1S(=O)(=O)C1CCN(c2nc(Cc3cccc(C)c3)cs2)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 6/20 0.39
DRD4 P21917 5/20 0.39
DRD3 P35462 5/20 0.39
GAA P10253 3/20 0.38
ALOX15 P16050 1/20 0.38
KMT2A Q03164 3/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 3/20 0.34
MAPT P10636 2/20 0.34
LMNA P02545 1/20 0.34
PPARG P37231 1/20 0.34
GFER P55789 1/20 0.34
NCOA2 Q15596 1/20 0.34
NCOA1 Q15788 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34
ADRA1D P25100 1/20 0.34
ADRA1A P35348 1/20 0.34
ADRA1B P35368 1/20 0.34
HTT P42858 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3004621 0.95 DRD2 (0.41) DRD2DRD4DRD3GAAALOX15
SCHEMBL3000603 0.93 GAA (0.39) DRD2DRD4DRD3GAAALOX15
SCHEMBL3015950 0.92 DRD2 (0.39) DRD2DRD4DRD3GAAALDH1A1
SCHEMBL3007655 0.92 DRD2 (0.45) DRD2DRD4DRD3GAAALOX15
SCHEMBL3009529 0.91 ALDH1A1 (0.41) GAAKMT2AALDH1A1MAPTLMNA
SCHEMBL3019945 0.91 GAA (0.39) DRD2DRD4DRD3GAAALOX15
SCHEMBL3022242 0.90 MAPK1 (0.38) DRD2KDM4EALDH1A1MAPTADRA1D
SCHEMBL3013312 0.90 GAA (0.39) DRD2DRD4DRD3GAAALOX15
SCHEMBL3006097 0.89 GAA (0.38) DRD2DRD4DRD3GAAALOX15
SCHEMBL3019551 0.89 ALDH1A1 (0.41) DRD2DRD4DRD3GAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA DRD2 573/4885DRD4 1124/4885DRD3 682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.